Phase 2 multicentre study of single-agent ofatumumab in previously
untreated follicular lymphoma: CALGB 50901 (Alliance)
- Citation:
- Br. J. Haematol. vol 185 (1) 53-64
- Year:
- 2019
- Type:
- Manuscript
- Funding:
- NCTN
- Endpoint:
- Primary
- Analysis:
- Primary
- Data Sharing:
- No-Data-Sharing
- Status:
- Presented/Published
- Citation Status:
- pmc-release
- Note:
- Methodological:
- No
- Biospecimen:
- No
- SDC:
- No
- Book Volume:
- 8
- Parents:
- 2391
- Children:
- None
- Pharmas:
- GSK(Novartis)
- Grants:
- U10CA180821, U10CA180882, U10CA180833, U10CA180836, U10CA180857, UG1CA189830
- Corr. Author:
- Authors:
- Cara A. Rosenbaum Sin-Ho Jung Brandelyn Pitcher Nancy L. Bartlett Sonali M. Smith Eric Hsi Nina Wagner-Johnston Sachdev P. Thomas John P. Leonard Bruce D. Cheson
- Networks:
- CAPITAL, KAISER, LAPS-IL057, LAPS-MD017, LAPS-MN026, LAPS-MO011, NY018
- Study
- CALGB-50901
- Multiple Studies, or Legacy Studies in Alliance Study:
- Phases:
- 2
- Keywords:
- follicular lymphoma, previously untreated, immunotherapy, monoclonal antibody, ofatumumab